Expert review of pharmacoeconomics & outcomes research
-
Expert Rev Pharmacoecon Outcomes Res · Apr 2015
Convergence of decision rules for value-based pricing of new innovative drugs.
Given the high costs of innovative new drugs, most European countries have introduced policies for price control, in particular value-based pricing (VBP) and international reference pricing. The purpose of this study is to describe how profit-maximizing manufacturers would optimally adjust their launch sequence to these policies and how VBP countries may best respond. ⋯ Based on the manufacturer's rationale, it is best for VBP countries in Europe to implicitly collude in the long term and set cost-effectiveness thresholds at the level of the lowest acceptable VBP country. This way, international reference pricing countries would also converge towards the lowest acceptable threshold in Europe.
-
Expert Rev Pharmacoecon Outcomes Res · Apr 2015
Cost-effectiveness of bronchial thermoplasty in commercially-insured patients with poorly controlled, severe, persistent asthma.
We examined the cost-effectiveness of treating poorly controlled, severe, persistent asthma patients with bronchial thermoplasty (BT), a novel technology that uses thermal energy to reduce airway smooth muscle mass, with 5-year outcome data demonstrating a durable reduction in asthma exacerbations. ⋯ BT is a cost-effective treatment option for patients with poorly controlled, severe, persistent asthma.
-
Expert Rev Pharmacoecon Outcomes Res · Feb 2015
Review of ongoing initiatives to improve prescribing efficiency in China; angiotensin receptor blockers as a case history.
Pharmaceutical expenditure is rising by 16% per annum in China and is now 46% of total expenditure. Initiatives to moderate growth include drug pricing regulations and encouraging international non-proprietary name prescribing. However, there is no monitoring of physician prescribing quality and perverse incentives. ⋯ Considerable opportunities to improve prescribing efficiency in China.
-
Expert Rev Pharmacoecon Outcomes Res · Jan 2015
The impact of South Korea's new drug-pricing policy on market competition among off-patent drugs.
A new pricing policy was introduced in Korea in April 2012 with the aim of strengthening competition among off-patent drugs by eliminating price gaps between originators and generics. ⋯ The new pricing policy made no impact on competition among off-patent drugs. Competition in the off-patent market cannot be enhanced unless both supply and demand side measures are coordinated.